{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T04:59:29Z","timestamp":1787806769757,"version":"build-2784847793"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T00:00:00Z","timestamp":1706659200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003921","name":"Department of Health and Aged Care, Australian Government","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003921","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000923","name":"Australian Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000923","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.eclinm.2024.102489","type":"journal-article","created":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T16:07:45Z","timestamp":1709050065000},"page":"102489","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Viral hepatitis testing and treatment in community pharmacies: a systematic review and meta-analysis"],"prefix":"10.1016","volume":"69","author":[{"given":"Mark J.","family":"Hayes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Beavon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Traeger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"Dillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Radley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5341-1055","authenticated-orcid":false,"given":"Suzanne","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqui","family":"Richmond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Higgs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret E.","family":"Hellard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph S.","family":"Doyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eclinm.2024.102489_bib1","series-title":"Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021. Accountability for the global health sector stategies 2016-2021: actions for impact","author":"World Health Organization","year":"2021"},{"key":"10.1016\/j.eclinm.2024.102489_bib2","series-title":"Global health sector strategy on viral hepatitis 2016-2020","author":"World Health Organization","year":"2016"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102489_bib3","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/add.13593","article-title":"Effectiveness of pharmacy-based needle\/syringe exchange programme for people who inject drugs: a systematic review and meta-analysis","volume":"112","author":"Sawangjit","year":"2017","journal-title":"Addiction"},{"issue":"4","key":"10.1016\/j.eclinm.2024.102489_bib4","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.japh.2016.03.006","article-title":"The impact of pharmacist immunization programs on adult immunization rates: a systematic review and meta-analysis","volume":"56","author":"Baroy","year":"2016","journal-title":"J\u00a0Am Pharm Assoc (2003)"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102489_bib5","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40545-020-00291-7","article-title":"Geographical accessibility of medicines: a systematic literature review of pharmacy mapping","volume":"14","author":"Tharumia Jagadeesan","year":"2021","journal-title":"J\u00a0Pharm Policy Pract"},{"issue":"8","key":"10.1016\/j.eclinm.2024.102489_bib6","article-title":"The positive pharmacy care law: an area-level analysis of the relationship between community pharmacy distribution, urbanity and social deprivation in England","volume":"4","author":"Adam","year":"2014","journal-title":"BMJ Open"},{"issue":"4","key":"10.1016\/j.eclinm.2024.102489_bib7","first-page":"846","article-title":"\u2018Standing outside the Junkie Door\u2019\u2014service users' experiences of using community pharmacies to access treatment for opioid dependency","volume":"39","author":"Radley","year":"2017","journal-title":"J\u00a0Public Health"},{"issue":"12","key":"10.1016\/j.eclinm.2024.102489_bib8","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1080\/14737159.2017.1400385","article-title":"Hepatitis C point-of-care diagnostics: in search of a single visit diagnosis","volume":"17","author":"Grebely","year":"2017","journal-title":"Expert Rev Mol Diagn"},{"issue":"10","key":"10.1016\/j.eclinm.2024.102489_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/cells9102233","article-title":"Point-of-Care tests for hepatitis B: an overview","volume":"9","author":"Xiao","year":"2020","journal-title":"Cells"},{"issue":"8","key":"10.1016\/j.eclinm.2024.102489_bib10","doi-asserted-by":"crossref","first-page":"e559","DOI":"10.1016\/S2214-109X(16)30130-9","article-title":"Acceptability and feasibility of a screen-and-treat programme for hepatitis B virus infection in the Gambia: the Prevention of Liver Fibrosis and Cancer in Africa (PROLIFICA) study","volume":"4","author":"Lemoine","year":"2016","journal-title":"Lancet Glob Health"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102489_bib11","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/liv.15095","article-title":"Differences in the hepatitis C virus cascade of care and time to initiation of therapy among vulnerable subpopulations using a mobile unit as point-of-care","volume":"42","author":"Valencia","year":"2022","journal-title":"Liver Int"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102489_bib12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0227041","article-title":"Eligibility for hepatitis B antiviral therapy among adults in the general population in Zambia","volume":"15","author":"Vinikoor","year":"2020","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.eclinm.2024.102489_bib13","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1097\/MEG.0000000000001180","article-title":"Prevalence of hepatitis B and hepatitis C infection from a population-based study in Southern India","volume":"30","author":"Shanmugam","year":"2018","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.eclinm.2024.102489_bib14","article-title":"Hepatitis C identification and treatment in rural Pennsylvania, USA","volume":"24","author":"Stainbrook","year":"2021","journal-title":"Prev Med Rep"},{"issue":"6","key":"10.1016\/j.eclinm.2024.102489_bib15","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1080\/09540121.2016.1164290","article-title":"Implementation of rapid HIV and HCV testing within harm reduction programmes for people who inject drugs: a pilot study","volume":"28","author":"Fern\u00e0ndez-L\u00f3pez","year":"2016","journal-title":"AIDS Care"},{"issue":"3","key":"10.1016\/j.eclinm.2024.102489_bib16","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/jvh.13634","article-title":"Point-of-care hepatitis C testing and treatment strategy for people attending harm reduction and addiction centres for hepatitis C elimination","volume":"29","author":"Forns","year":"2022","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.eclinm.2024.102489_bib17","article-title":"Maternal hepatitis B infection burden, comorbidity and pregnancy outcome in a low-income population on the Myanmar-Thailand border: a retrospective cohort study","volume":"2019","author":"Bierhoff","year":"2019","journal-title":"J\u00a0Pregnancy"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102489_bib18","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.4314\/ahs.v19i2.17","article-title":"Seroprevalence of HBV among people living with HIV in Anyigba, Kogi State, Nigeria","volume":"19","author":"Omatola","year":"2019","journal-title":"Afr Health Sci"},{"issue":"4","key":"10.1016\/j.eclinm.2024.102489_bib19","doi-asserted-by":"crossref","first-page":"e431","DOI":"10.1016\/S2214-109X(20)30505-2","article-title":"Decentralisation, integration, and task-shifting in hepatitis C virus infection testing and treatment: a global systematic review and meta-analysis","volume":"9","author":"Oru","year":"2021","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.eclinm.2024.102489_bib20","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"7414","key":"10.1016\/j.eclinm.2024.102489_bib21","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.eclinm.2024.102489_bib22","series-title":"Joanna Briggs institute reviewer's manual","article-title":"Chapter 3: systematic reviews of effectiveness","author":"Tufanaru","year":"2017"},{"issue":"10","key":"10.1016\/j.eclinm.2024.102489_bib23","first-page":"2127","article-title":"Methodological quality of case series studies: an introduction to the JBI critical appraisal tool","volume":"18","author":"Munn","year":"2020","journal-title":"JBI Evid Synth"},{"issue":"12","key":"10.1016\/j.eclinm.2024.102489_bib24","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1111\/apt.16953","article-title":"Reaching people receiving opioid agonist therapy at community pharmacies with hepatitis C virus: an international randomised controlled trial","volume":"55","author":"Byrne","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.eclinm.2024.102489_bib25","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1136\/flgastro-2016-100776","article-title":"A\u00a0quasi-experimental evaluation of dried blood spot testing through community pharmacies in the Tayside region of Scotland","volume":"8","author":"Radley","year":"2017","journal-title":"Frontline Gastroenterol"},{"key":"10.1016\/j.eclinm.2024.102489_bib26","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.drugpo.2017.05.042","article-title":"DOT-C: a cluster randomised feasibility trial evaluating directly observed anti-HCV therapy in a population receiving opioid substitute therapy from community pharmacy","volume":"47","author":"Radley","year":"2017","journal-title":"Int J Drug Policy"},{"issue":"9","key":"10.1016\/j.eclinm.2024.102489_bib27","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/S2468-1253(20)30120-5","article-title":"Clinical effectiveness of pharmacist-led versus conventionally delivered antiviral treatment for hepatitis C virus in patients receiving opioid substitution therapy: a pragmatic, cluster-randomised trial","volume":"5","author":"Radley","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.eclinm.2024.102489_bib28","series-title":"The development of community pharmacy integrated test and treat service for hepatitis c (Copitt)","author":"Boothman","year":"2019"},{"issue":"8","key":"10.1016\/j.eclinm.2024.102489_bib29","first-page":"765","article-title":"Integrating community pharmacy testing for hepatitis c with specialist care","volume":"8","author":"Buchanan","year":"2016","journal-title":"Clin Pharm"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102489_bib30","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/jvh.13207","article-title":"The testing of people with any risk factor for hepatitis C in community pharmacies is cost-effective","volume":"27","author":"Buchanan","year":"2020","journal-title":"J\u00a0Viral Hepat"},{"issue":"4","key":"10.1016\/j.eclinm.2024.102489_bib31","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.japh.2017.04.463","article-title":"Pharmacists performing hepatitis C antibody point-of-care screening in a community pharmacy: a pilot project","volume":"57","author":"Dong","year":"2017","journal-title":"J\u00a0Am Pharm Assoc"},{"issue":"5","key":"10.1016\/j.eclinm.2024.102489_bib32","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1007\/s11096-022-01444-1","article-title":"Point-of-care HIV and hepatitis screening in community pharmacies: a quantitative and qualitative study","volume":"44","author":"Figueira","year":"2022","journal-title":"Int J Clin Pharm"},{"key":"10.1016\/j.eclinm.2024.102489_bib33","first-page":"37","author":"Fong","year":"2019"},{"key":"10.1016\/j.eclinm.2024.102489_bib34","first-page":"63","author":"Fuchs","year":"2020"},{"issue":"1525","key":"10.1016\/j.eclinm.2024.102489_bib35","first-page":"74","article-title":"Feasibility and outcomes of a hepatitis C screening programme in community pharmacies","volume":"133","author":"Gauld","year":"2020","journal-title":"N\u00a0Z Med J"},{"key":"10.1016\/j.eclinm.2024.102489_bib36","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ijregi.2023.08.006","article-title":"Impact of COVID-19 on hepatitis B screening in Sierra Leone: insights from a community pharmacy model of care","volume":"9","author":"Ghazzawi","year":"2023","journal-title":"IJID Regions"},{"key":"10.1016\/j.eclinm.2024.102489_bib37","series-title":"Diagnosing viral hepatitis in the community: a 3-month pharmacy testing pilot","author":"Hepatitis C Trust","year":"2010"},{"issue":"4","key":"10.1016\/j.eclinm.2024.102489_bib38","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.japh.2023.04.001","article-title":"Innovating the model for student pharmacists to increase access to hepatitis C testing (project IMPACT)","volume":"63","author":"Januszka","year":"2023","journal-title":"J\u00a0Am Pharm Assoc"},{"key":"10.1016\/j.eclinm.2024.102489_bib39","article-title":"The role of community pharmacies in the HIV and HCV care continuum","volume":"9","author":"Kherghehpoush","year":"2023","journal-title":"Explor Res Clin Soc Pharm"},{"key":"10.1016\/j.eclinm.2024.102489_bib40","doi-asserted-by":"crossref","first-page":"E83","DOI":"10.5888\/pcd19.220129","article-title":"Implementation and evaluation of a collaborative, pharmacy-based hepatitis C and HIV screening program","volume":"19","author":"Klepser","year":"2022","journal-title":"Prev Chronic Dis"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102489_bib41","first-page":"98","article-title":"Hepatitis C point-of-care screening in retail pharmacies in the United States","volume":"13","author":"Kugelmas","year":"2017","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.eclinm.2024.102489_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2020.102811","article-title":"Eradicating hepatitis C: are novel screening strategies for people who inject drugs cost-effective?","volume":"82","author":"Manca","year":"2020","journal-title":"Int J Drug Policy"},{"key":"10.1016\/j.eclinm.2024.102489_bib43","series-title":"Testing and treatment for hepatitis C in the community pharmacy setting: an opportunity not to be missed? EASL: The Digital International Liver Congress","first-page":"S324","author":"Palmer","year":"2020"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102489_bib44","first-page":"S294","article-title":"Depist C pharma, an innovative outreach HCV screening project in pharmacy for drug users and general population. European Association for the Study of the Liver","volume":"75","author":"Remy","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.eclinm.2024.102489_bib45","series-title":"Pharmacy-based molecular point-of-care testing for hepatitis C (HCV) in high-risk patients: feasibility and linkage to care. EASL: the Digital International Liver Congress","first-page":"S307","author":"Rogers","year":"2020"},{"key":"10.1016\/j.eclinm.2024.102489_bib46","series-title":"'I just never wanted them to feel uncomfortable'\u2013barriers to pharmact-based identification and treatment of hepatitis C in Victorian, British Columbia","author":"Selfridge","year":"2022"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102489_bib47","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1186\/s12879-023-08362-1","article-title":"Hepatitis C virus screening in community pharmacies: results on feasibility from a Swiss pilot","volume":"23","author":"St\u00e4mpfli","year":"2023","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.eclinm.2024.102489_bib48","series-title":"Collaborative working with community pharmacies increases testing and enhances access to direct acting antiviral (DAA) therapy for hepatitis C","author":"Stephen","year":"2019"},{"key":"10.1016\/j.eclinm.2024.102489_bib49","series-title":"HCV testing in NSP (needle and syringe provision) community pharmacies pilot (phase 1)","author":"Verma","year":"2018"},{"key":"10.1016\/j.eclinm.2024.102489_bib50","series-title":"HCV testing in\u00a0NSP (needle and syringe provision) community pharmacies pilot (phase 2)","author":"Verma","year":"2019"},{"issue":"7","key":"10.1016\/j.eclinm.2024.102489_bib51","doi-asserted-by":"crossref","DOI":"10.3390\/v14071555","article-title":"A\u00a0testing campaign intervention consisting of peer-facilitated engagement, point-of-care HCV RNA testing, and linkage to nursing support to enhance hepatitis C treatment uptake among people who inject drugs: the ETHOS engage study","volume":"14","author":"Conway","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.eclinm.2024.102489_bib52","article-title":"Rapid hepatitis C virus point-of-care RNA testing and treatment at an integrated supervised consumption service in Toronto, Canada: a prospective, observational cohort study","volume":"22","author":"Lettner","year":"2023","journal-title":"Lancet Reg Health Am"},{"issue":"1525","key":"10.1016\/j.eclinm.2024.102489_bib53","first-page":"84","article-title":"Point-of-care rapid testing for hepatitis C antibodies at New Zealand needle exchanges","volume":"133","author":"Noller","year":"2020","journal-title":"N\u00a0Z Med"},{"key":"10.1016\/j.eclinm.2024.102489_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2022.103668","article-title":"Feasibility of hepatitis C virus testing and linkage in community supervision offices: great potential but persistent challenges","volume":"103","author":"Jacka","year":"2022","journal-title":"Int J Drug Policy"},{"issue":"5","key":"10.1016\/j.eclinm.2024.102489_bib55","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S2468-1253(21)00472-6","article-title":"Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study","volume":"7","author":"Blach","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102489_bib56","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1186\/s12913-019-4635-7","article-title":"A\u00a0systematic review and meta-analysis of community and primary-care-based hepatitis C testing and treatment services that employ direct acting antiviral drug treatments","volume":"19","author":"Radley","year":"2019","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102489_bib57","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13722-021-00260-8","article-title":"\u2018Treat my whole person, not just my condition\u2019: qualitative explorations of hepatitis C care delivery preferences among people who inject drugs","volume":"16","author":"Tsui","year":"2021","journal-title":"Addict Sci Clin Pract"},{"issue":"12","key":"10.1016\/j.eclinm.2024.102489_bib58","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/S1473-3099(16)30208-0","article-title":"Interventions to optimise the care continuum for chronic viral hepatitis: a systematic review and meta-analyses","volume":"16","author":"Zhou","year":"2016","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102489_bib59","doi-asserted-by":"crossref","first-page":"81","DOI":"10.5334\/aogh.2848","article-title":"Point-of-Care tests for hepatitis B are associated with A higher linkage to care and lower cost compared to venepuncture sampling during outreach screenings in an Asian migrant population","volume":"86","author":"Ho","year":"2020","journal-title":"Ann Glob Health"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102489_bib60","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-96350-3","article-title":"A\u00a0novel model of care\u00a0for simplified testing of HBV in African communities during the COVID-19 pandemic in Spain","volume":"11","author":"Picchio","year":"2021","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.eclinm.2024.102489_bib61","first-page":"485","article-title":"The role of pharmacists in the comprehensive care of patients with hepatitis C: a systematic review","volume":"35","author":"Ledezma-Morales","year":"2020","journal-title":"Rev Colomb Gastroenterol"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537024000683?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537024000683?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:39:28Z","timestamp":1781642368000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537024000683"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":61,"alternative-id":["S2589537024000683"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2024.102489","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Viral hepatitis testing and treatment in community pharmacies: a systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2024.102489","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102489"}}